Nexentis Technologies Inc. (NXTS) stock analysis
Basic Materials · Agricultural Inputs
From the 10-K filed 2026-03-31
What protects it: the moat
Management claims the MITOLINE algorithm provides reliable models for all 53 SLC25A proteins where AI systems struggle to predict functional conformational changes.
The proprietary MITOLINE algorithm uses specific sequence and structure anchor points to create reliable 3D models for the SLC25A protein family, which management claims current AI-based systems cannot accurately predict due to multiple functional conformations.
The business maintains exclusive access to this platform-based discovery model to identify hit molecules for Non-Small Cell Lung Cancer and pancreatic cancer, aimed at overcoming drug resistance in existing chemotherapy and EGFR therapies.
What could damage it
Earnings are permanently impaired if development results fail to support patents, as seen when it withdrew two U.S. applications for its primary hit molecule in 2025.
Revenue is permanently impaired if clinical or laboratory results fail to validate early-stage chemical scaffolds, leading to the loss of intellectual property protection.
In 2025, the company was forced to withdraw two U.S. provisional patent applications for its primary hit molecule because recent scientific data failed to support the claims, effectively resetting its lead optimization campaign.
About Nexentis Technologies Inc.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.